07:07 EST 10 Mar 2016 | Edison Investment Research .
Edison Investment Research - Pharmaceutical & Healthcare - PharmaMar:
*.- PharmaMar’s increasing investment in its promising oncology pipeline is supported by growing Yondelis revenue that will be further buoyed by recent approvals in the US, Japan and elsewhere, as well as by refinancing of its short-term debt.
*.- Phase III data for Aplidin in multiple myeloma, expected later this month, could be a significant catalyst for the stock.
*.- Our valuation is unchanged at €1.07bn or €4.82 per share ahead of this.
*.- If the results are positive, we expect filing for approval in Q416.
*.- Fully enrol PM1183 ovarian cancer Phase III 2016 .
...
